2005, Number 2
<< Back Next >>
Rev Invest Clin 2005; 57 (2)
Histocompatibility main complex biological function
López-Martínez A, Chávez-Muñoz C, Granados J
Language: Spanish
References: 42
Page: 132-141
PDF size: 95.97 Kb.
Text Extraction
No Abstract
REFERENCES
Klein J, Sato A. Birth of the major histocompatibility complex. Scand J Immunol 1998; 47: 199.
Beck S, Hanson I, Kelly A, Khurshid F, Radley E, Trowsdale J. DNA sequence analysis of 66 KB of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol 1992; 228: 433.
Hunt JS, Orr HT. HLA and maternal-fetal recognition. FASEB J 1992; 6: 2344.
Kendall E, Sargent CA, Campbell RD. MHC contains a new cluster of genes between the HLA-D and complement C4 loci. Nucleic Acids Res 1990; 18: 7251.
Brown J, Jardetzky T, Gorga J, et al. Three-dimensional structure of the human class I MHC antigen HLA-DR1. Nature 1993; 364: 33.
Madden D. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995; 13: 587.
Strominger JL, Wiley DC. The class II proteins of the human major histocompatibility complex. JAMA 1995; 274: 1074.
Engelhard VA. Structure of peptides associated with class I and Class II MHC molecules. Annu Rev Immunol 1994; 12: 181.
Jackson MR, Peterson PA. Assembly and intracellular transport of MHC class I molecules. Annu Rev Cell Biol 1993; 9: 207.
Cresswell P. Assembly, transport, and function of MCH class II molecules. Ann Rev Immunol 1994; 12: 259.
Sebzda E, Mariathasan S, Ohtek TI, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol 1996; 17: 829.
Kruisbeck AM. Regulation of T cell development by the thymic microenvironment. Semin Immunol 1999; 11: 1.
Murphy B, Sayegh MH. Why do we reject a graft? Mechanisms of recognition of transplantation antigens. Transpl Rev 1996; 10: 150.
Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med 2002; 8: 220.
Heath W, Hurd N, Carbone F, et al. Peptides dependent recognition of H-2K by alloreactive cytotoxic T lymphocytes. Nature 1989; 341: 749.
Clayberger C. Immunosupressive peptides corresponding to MHC class I sequences. Curr Opin Immunol 1995; 7: 644.
Murphy B, Akalin E, Watschiger B, et al. Inhibition of the alloimmune response with synthetic non-polymorphic class II MHC peptides. Transplant Proc 1995; 27: 409.
Remuzzi G, Perico N, Carpenter CB, et al. The thymic way to transplantation tolerance. J Am Soc Nephrol 1995; 5: 1639.
Azuma H, Heemann UW, Tullius SG, Tilney NL. Cytokines and adhesion molecules in chronic rejection. Clin Transplant 1994; 8: 168.
Mossmann TR. Properties and functions of interleukin-10. Adv Immunol 1994; 56: 1.
Heeman UW, Tullius SG. Azuma H, Kupiec-Weglinski J, Tilney NL. Adhesion molecules and transplantation. Ann Surg 1994; 219: 4.
Rositer H, Alon R, Kupper TS. Selectins, T cell rolling and inflammation. Mol Med Today 1997; 3: 214.
Coulin RB. Cellular and molecular mechanism of allograft rejection. Annu Rev Med 1990; 41: 361.
Newton-Nash DK. The molecular basis of allorecognition assessment of the involvement of peptide. Hum Immunol 1994; 41: 105.
Moolenaar W, Brujin JA, Schrama E, et al. T-cell receptors and ICAM-1 expression in renal allografts during rejection. Transplant Int 1991; 4: 140.
Briscoe DM, Schoen FJ, Rice GE, et al. Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplant 1991; 51: 537.
Adams DH, Mainolfi E, Elias, et al. Detection of circulating intercellular adhesion molecule-1 after liver transplantation- evidence of local release within the liver during graft rejection. Transplant 1993; 55: 83.
Damle NK, Klussman K, Leytze G, et al. Co-stimulation via VCAM-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell Immunol 1993; 148: 144.
Dallman MJ. The cytokine network and regulation of the immune response to organ transplants. Transplant Rev 1992; 6: 209.
Lowry RP, Blais D. Tumor necrosis factor-alpha in rejecting rat cardiac allografts. Transplant Proc 1988; 20: 245.
Parneau J, Priestly C, Fabre J, et al. Effects of gamma interferon and interleukin 2, and of gamma interferon antibodies in the rat immune response against allografts. Transplant Proc 1989; 21: 999.
Dallman MJ, Shiho O, Page TH, et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79.
Hernandez-Fuentes MP, Lechler RI. Chronic graft loss. Immunological and non-immunological factors. Contrib Nephrol 2005; 146: 54.
Opelz G, for the Collaborative Transplant Study. Strength of HLA-A, HLA-B, and HLA-DR mismatches in relation to short- and long-term kidney graft survival. Transplant Int 1991; 5(Suppl. 1); S621.
Fishman JA. BK-virus nephropaty-polyomavirus adding insult to injury. N Engl J Med 2002; 347: 527.
Lemström K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts; after cytomegalovirus infection. Circulation 1995; 92: 2594.
O’Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet ii 1988; 302-4.
Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398.
Autieri MV. Allograft induced proliferation of vascular smooth muscle cells: potential targets for treating transplant vasculopathy. Curr Vasc Pharmacol 2003; 1: 1.
Nocera A, Tagliamacco A, De Palma R, et al. Cytokine mRNA expression in chronically rejected human renal allografts. Clin Transplant 2004; 18: 564.
Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137.
Lindner V, Lappi D, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106.